Loading…
Voyager Therapeutics, Inc. is projected to decline to $3.03 by 2027, a 0% move from its current price of $3.03. VYGR is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/2/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 4 | $2.95 | $3.03 | $3.11 | +0.04% |
| Aug 5 | $2.92 | $3.03 | $3.15 | +0.08% |
| Aug 6 | $2.90 | $3.03 | $3.17 | +0.12% |
| Aug 7 | $2.88 | $3.03 | $3.20 | +0.16% |
| Aug 8 | $2.86 | $3.04 | $3.22 | +0.19% |
| Aug 9 | $2.85 | $3.04 | $3.24 | +0.23% |
| Aug 10 | $2.84 | $3.04 | $3.25 | +0.27% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $2.84 | $3.04 | $3.25 | +0.27% |
| Week 2 | $2.76 | $3.05 | $3.36 | +0.55% |
| Week 3 | $2.71 | $3.05 | $3.44 | +0.82% |
| Week 4 | $2.67 | $3.06 | $3.52 | +1.09% |
| Week 5 | $2.63 | $3.07 | $3.58 | +1.37% |
| Week 6 | $2.60 | $3.08 | $3.65 | +1.64% |
| Week 7 | $2.57 | $3.09 | $3.71 | +1.92% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Voyager Therapeutics, Inc. (VYGR) is a biotechnology company that focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease.
The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Transition Bio, Inc.
for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
Voyager Therapeutics, Inc. is a biotechnology company focused on neurological diseases. It trades in the Healthcare space and is currently priced at $3.20 with a market cap of $193.35M, ranking 3842.
The current price and forecast imply a long-run price trajectory that moves from a neutral near-term toward stronger bullish readings later in the decade. The year-by-year forecast shows substantial upside by 2050, with a 2050 average of $14.19 and a maximum of $26.80, producing a projected long-run ROI of 343.5 and a bullish sentiment in the distant horizon. In the near term, the stock’s price action is framed by modest near-term momentum and defined support and resistance levels.
The asset sits within the specified 30-day range and exhibits elevated, near-term volatility.
A major floor 17.8% below — a decisive break under it would weaken the trend.
Price is testing support right now (1.0% away) — a key level to hold.
The nearest ceiling, 24.8% above — a clean break opens room to run.
A major ceiling 39.9% above — clearing it would confirm fresh momentum.
Key VYGR support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of VYGR market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $3.06 | Sell | $3.06 | Sell |
| MA 10 | $3.08 | Sell | $3.10 | Sell |
| MA 20 | $3.24 | Sell | $3.21 | Sell |
| MA 50 | $3.47 | Sell | $3.43 | Sell |
| MA 100 | $3.74 | Sell | $3.62 | Sell |
| MA 200 | $3.93 | Sell | $3.83 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 38.76 | Neutral |
| Stoch RSI (14) | 62.99 | Neutral |
| CCI (20) | -69.03 | Neutral |
| Williams %R (14) | -85.00 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | -5.31 | Sell |
| Bollinger %B (20,2) | 0.29 | Neutral |
| Stochastic %K (14) | 15.00 | Buy |
| TRIX (15) | -0.58 | Sell |
| Awesome (5,34) | -0.34 | Sell |
| Ultimate (7,14,28) | 39.30 | Neutral |
| Momentum (10) | -0.14 | Sell |
| Aroon Osc (25) | -64.00 | Sell |
| Hull MA (9) | 3.04 | Sell |
| ADX (14) | 19.67 | Neutral |
| ATR (14) | 0.08 | Info |
The near-term technical picture is bearish, with RSI14 at 40. The stock trades, on average, below its short- and longer-term moving averages, with SMA50 at $3.68 and SMA200 at $4.04. Support is identified at $3.16 and resistance at $3.78, framing a near-term path that could test these levels.
The 30-day range spans from $2.64 to $3.87, and annualized volatility sits at 60, indicating notable near-term variability.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $3.00 | $3.03 | $3.94 | 0% | Neutral | |
| $2.42 | $3.03 | $3.99 | 0% | Neutral | |
| $2.54 | $3.26 | $4.45 | +7% | Neutral | |
| $2.93 | $3.84 | $5.39 | +27% | Bullish | |
| $3.12 | $4.17 | $6.00 | +38% | Bullish | |
| $3.25 | $4.42 | $6.50 | +46% | Bullish | |
| $3.28 | $4.54 | $6.79 | +50% | Bullish | |
| $3.24 | $4.55 | $6.92 | +50% | Bullish | |
| $3.23 | $4.60 | $7.11 | +52% | Bullish | |
| $3.57 | $5.16 | $8.08 | +70% | Bullish | |
| $4.22 | $6.50 | $10.81 | +114% | Bullish | |
| $7.87 | $13.49 | $24.49 | +345% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $3.00 | $3.03 | $3.74 | +0.00% |
| September 2026 | $2.71 | $3.20 | $3.89 | +5.67% |
| October 2026 | $2.64 | $3.14 | $3.85 | -1.95% |
| November 2026 | $2.59 | $3.10 | $3.83 | -1.36% |
| December 2026 | $2.64 | $3.17 | $3.94 | +2.23% |
Click any year to see its month-by-month VYGR forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect VYGR to range from $3.00 to $3.94 through 2026. The $3.03 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The VYGR price prediction for 2027 points to an average of $3.03 (low $2.42, high $3.99) — a potential decline of 0% on today's $3.03. Price action looks broadly range-bound.
In 2028, VYGR is projected to trade between $2.54 and $4.45, averaging $3.26 — a potential gain of +7% from today's $3.03. That is up +8% on the projected 2027 average. A consolidation phase looks the most probable path here.
Voyager Therapeutics, Inc.'s 2029 outlook centres on $3.84, within a $2.93 to $5.39 range. That is up +18% on the projected 2028 average. That marks a +27% change versus current levels. Momentum favours further upside here.
By 2030, VYGR could reach as high as $6.00, with a base case around $4.17 and support toward $3.12 — roughly +38% from $3.03. Buyers look set to stay in control over this stretch.
Expect VYGR to range from $3.25 to $6.50 through 2031. The $4.42 average target implies a +46% move from current prices. That is up +6% on the projected 2030 average. Momentum favours further upside here.
The VYGR price prediction for 2032 points to an average of $4.54 (low $3.28, high $6.79) — a potential gain of +50% on today's $3.03. Buyers look set to stay in control over this stretch.
In 2033, VYGR is projected to trade between $3.24 and $6.92, averaging $4.55 — a potential gain of +50% from today's $3.03. That is up 0% on the projected 2032 average. Momentum favours further upside here.
Voyager Therapeutics, Inc.'s 2034 outlook centres on $4.60, within a $3.23 to $7.11 range. That is up +1% on the projected 2033 average. That marks a +52% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, VYGR could reach as high as $8.08, with a base case around $5.16 and support toward $3.57 — roughly +70% from $3.03. Momentum favours further upside here.
Expect VYGR to range from $4.22 to $10.81 through 2040. The $6.50 average target implies a +114% move from current prices. That is up +26% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The VYGR price prediction for 2050 points to an average of $13.49 (low $7.87, high $24.49) — a potential gain of +345% on today's $3.03. Momentum favours further upside here.
Investing $1,000 in VYGR today (≈ 330.033003 VYGR) could be worth
$4,452.16
+$3,452.16 (+345%) by 2050 · US Dollar
Based on the average projected VYGR price of $13.49 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in VYGRwould be worth at today's price.
$1,000 invested in VYGR on Jul 31, 2025 (≈ 313.479618 VYGR) would be worth
$949.84
-$50.16 (-5.0%) today · 0.95× · US Dollar
Based on a VYGR entry price of $3.19 vs. today's $3.03.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $3.1 | $977.42 | -2.3% |
| 1 month ago | $3.6 | $841.67 | -15.8% |
| 3 months ago | $3.76 | $805.85 | -19.4% |
| 6 months ago | $4 | $757.5 | -24.3% |
| 1 year ago | $3.19 | $949.84 | -5.0% |
| All time (5.0y) ago | $3.18 | $952.83 | -4.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our VYGR forecast.
Our base-case forecast reaches $6.10 around 2040.
Implied market cap at $6.10: $368.57M
The multi-year forecast shows a bullish trajectory, with 2029 average at $4.11 and 2030 average at $4.33, rising toward 2040 and beyond. The 2030 forecast documents a max of $6.37 and a min of $3.18, yielding a 35.2 ROI and a bullish sentiment for that year. By 2040, the average rises to $6.91 with a projected max of $11.89 and a 116 ROI, maintaining a bullish outlook.
By 2050, the average reaches $14.19 with a max of $26.80 and a 343.5 ROI, continuing the bullish stance. The forecast sequence includes meaningful year-by-year upside through 2031–2035 and into the longer-horizon 2040 and 2050 periods, but these are estimates, not guarantees, and actual results may vary.
Tap a question to reveal the answer.
2030 avg $4.33, min $3.18, max $6.37, ROI 35.2, sentiment BULLISH.
The forecast shows a bullish path in 2030, 2040, and 2050 with rising averages and positive ROIs, but 2026 and some earlier years show neutral sentiment and modest gains; these are estimates, not guarantees.
Yes, the 2030 forecast lists a max of $6.37.
Min $3.16, avg $3.20, max $4.24; ROI 0; sentiment NEUTRAL.
Min $4.32, avg $6.91, max $11.89; ROI 116; sentiment BULLISH.
Voyager Therapeutics, Inc. Community Discussion
0Share your Voyager Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.